Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7237135 | 0.96 | F10 (0.42) | F10MEN1ALDH1A1KMT2AACE | |
| SCHEMBL5171227 | 0.77 | CNR1 (0.35) | KMT2ACHRM2CHRM1CHRM3 | |
| SCHEMBL7247690 | 0.77 | L3MBTL1 (0.44) | MEN1ALDH1A1KMT2A | |
| SCHEMBL1190098 | 0.76 | NR1I2 (0.36) | ALDH1A1 | |
| SCHEMBL7090877 | 0.75 | SIGMAR1 (0.36) | F10MEN1ALDH1A1KMT2ACHRM2 | |
| SCHEMBL7187879 | 0.75 | F10 (0.36) | F10ALDH1A1CHRM2CHRM1CHRM3 | |
| SCHEMBL7246586 | 0.74 | CHRM2 (0.52) | MEN1ALDH1A1KMT2ACHRM2CHRM4 | |
| SCHEMBL6982387 | 0.73 | F10 (0.45) | F10HTTCHRM2CHRM4CHRM1 | |
| SCHEMBL13383857 | 0.72 | F10 (0.53) | F10ACE | |
| SCHEMBL15855776 | 0.71 | NR1I2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544981-B2 | Anticoagulants, cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | F9, F7, F11 | F10 6/4885HTT 4829/4885MEN1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.